Colombian health Minister Alejandro Gaviria is expected to formally request market regulators SIC to remove the exclusivity license granted to drug-makers Novartis for a legal monopoly on the sale of Gilvec Imatin B, a drug used to treat various kinds of cancer and leukemia. In doing so, the minister revives an old argument between Colombian health authorities and the Swiss multinational over its Intellectual Property rights.
Four years ago, an SIC resolution denied Novartis the exclusive patent on the chemical. However, the company appealed the decision before the State Council, which finally granted the exclusivity license in 2012.
“We were proposing to buy the supply at 140 pesos per milligram… Novartis Labs sent a communiqué to the Health and Social Protection Ministry, stating they refused to enter into negotiations and rejecting the proposal by the Ministry”. For this reason, Gaviria has asked the SIC to once again remove the exclusive license which currently bars Colombian labs to churn out generic versions of the product. The SIC has within its powers the ability to remove this license, stripping Novartis of its monopoly protection, by invoking a need for internal competition to lower consumer prices.
Full Content: El Colombiano
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Subscribers Defend $4.7 Billion Antitrust Verdict Against NFL in Court Filings
Jul 19, 2024 by
CPI
Von der Leyen Calls for Competition Policy to Boost EU Companies’ Growth
Jul 19, 2024 by
CPI
Vermont AG Sues Pharmacy Benefit Managers Over Drug Prices
Jul 18, 2024 by
CPI
Australians Face Increased Stamp Prices Following ACCC Approval
Jul 18, 2024 by
CPI
Live Nation Seeks Dismissal of DOJ Antitrust Allegations
Jul 18, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Private Equity Roll-Up Schemes
Jun 28, 2024 by
CPI
The FTC’s Focus on Private Equity is Warranted
Jun 28, 2024 by
CPI
Unraveling the Roll-Up: Private Equity’s Misunderstood Investment Strategy
Jun 28, 2024 by
CPI
Antitrust Focus on Private Equity Funds and Serial Acquisitions
Jun 28, 2024 by
CPI
Private Equity Roll-Ups Amidst Heightened Antitrust Enforcement
Jun 28, 2024 by
CPI